Phase II Study of Surufatinib and Tislelizumab with Concurrent Chemoradiotherapy in Adults Aged 18 to 75 with Locally Advanced Unresectable Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining surufatinib and tislelizumab with concurrent chemoradiotherapy in patients who have unresectable, locally advanced stage III non-small cell lung cancer NSCLC. This phase II clinical trial aims to explore how this combination treatment, followed by consolidation therapy, may impact disease progression and survival outcomes for these patients. All participants will first receive concurrent chemoradiotherapy along with surufatinib and tislelizumab. Surufatinib is taken orally at 200 mg once daily for two weeks followed by a one-week break, forming a 21-day treatment cycle. Tislelizumab is given via intravenous infusion at 200 mg every three weeks, continuing for up to 12 months. Patients who show complete response, partial response, or stable disease after this initial treatment phase will continue with consolidation therapy using surufatinib and tislelizumab. During the study, participants will undergo assessments including tumor response evaluations, survival monitoring, and quality of life questionnaires. Researchers will also track treatment-related side effects and changes in minimal residual disease over time. The main outcome measured is the progression-free survival rate at two years. The study will follow participants for up to two years to gather comprehensive data on treatment effects and safety.

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer